$42.18 million in sales expected for LeMaitre Vascular, Inc. (NASDAQ:LMAT) this quarter

Brokerages expect LeMaitre Vascular, Inc. (NASDAQ:LMAT – Get Rating) to report sales of $42.18 million for the current quarter, according to Zacks. Five analysts have released LeMaitre Vascular earnings estimates, with the highest sales estimate at $43.51 million and the lowest estimate at $40.80 million. LeMaitre Vascular recorded sales of $40.67 million in the same quarter last year, suggesting a positive year-over-year growth rate of 3.7%. The company is due to announce its next quarterly earnings report on Monday, January 1.

On average, analysts expect LeMaitre Vascular to record annual sales of $164.26 million for the current year, with estimates ranging from $164.00 to $165.12 million. For next year, analysts expect the company to report sales of $174.42 million, with estimates ranging from $171.92 million to $178.07 million. Zacks sales averages are an average average based on a survey of sell-side analysts who follow LeMaitre Vascular.

LeMaitre Vascular (NASDAQ:LMAT – Get Rating) last released its quarterly results on Thursday, April 28. The medical device supplier reported earnings per share of $0.27 for the quarter, missing Thomson Reuters’ consensus estimate of $0.28 per ($0.01). The company posted revenue of $39.56 million for the quarter, versus analyst estimates of $38.65 million. LeMaitre Vascular had a return on equity of 12.42% and a net margin of 17.42%. The company’s revenue for the quarter increased 10.2% year over year. In the same period a year earlier, the company posted earnings per share of $0.28.

Several analysts have weighed in on the company recently. StockNews.com picked up coverage from LeMaitre Vascular in a Thursday, March 31 report. They set a “holding” rating for the company. Barrington Research reduced its target price on LeMaitre Vascular from $54.00 to $50.00 in a research report on Friday. Finally, Zacks Investment Research upgraded LeMaitre Vascular from a “hold” rating to a “buy” rating and set a target price of $50.00 for the company in a research report on Thursday. Two analysts gave the stock a hold rating and four gave the company a buy rating. According to MarketBeat, the company has a consensus rating of “Buy” and an average target price of $58.60.

NASDAQ:LMAT opened at $43.21 on Friday. The stock has a market capitalization of $948.55 million, a P/E ratio of 34.29, a PEG ratio of 3.39 and a beta of 1.32. The stock has a 50-day simple moving average of $45.73 and a 200-day simple moving average of $47.50. LeMaitre Vascular has a 1 year minimum of $39.48 and a 1 year maximum of $64.50.

The company also recently announced a quarterly dividend, which was paid on Thursday, March 24. Shareholders of record on Tuesday, March 8 received a dividend of $0.125 per share. This represents a dividend of $0.50 on an annualized basis and a dividend yield of 1.16%. This is an increase from LeMaitre Vascular’s previous quarterly dividend of $0.11. The ex-dividend date was Monday, March 7. LeMaitre Vascular’s dividend payout ratio is currently 39.68%.

Separately, insider Trent G. Kamke sold 7,929 shares of the company in a trade on Wednesday, March 2. The stock was sold at an average price of $48.22, for a total transaction of $382,336.38. The sale was disclosed in a filing with the Securities & Exchange Commission, accessible via this link. Company insiders own 16.50% of the company’s shares.

A number of institutional investors and hedge funds have recently changed their holdings in the company. BlackRock Inc. increased its stake in shares of LeMaitre Vascular by 5.9% in the third quarter. BlackRock Inc. now owns 3,115,834 shares of the medical device supplier valued at $165,420,000 after purchasing an additional 173,671 shares during the period. Copeland Capital Management LLC increased its stake in shares of LeMaitre Vascular by 7.1% in the fourth quarter. Copeland Capital Management LLC now owns 1,205,199 shares of the medical device supplier valued at $60,537,000 after purchasing an additional 80,112 shares during the period. Summit Creek Advisors LLC increased its stake in shares of LeMaitre Vascular by 21.0% in the fourth quarter. Summit Creek Advisors LLC now owns 361,359 shares of the medical device supplier valued at $18,151,000 after purchasing an additional 62,754 shares during the period. Renaissance Technologies LLC increased its stake in shares of LeMaitre Vascular by 123.8% in the third quarter. Renaissance Technologies LLC now owns 103,500 shares of the medical device supplier valued at $5,495,000 after purchasing an additional 57,261 shares during the period. Finally, ProShare Advisors LLC increased its equity stake in LeMaitre Vascular by 26.3% in the fourth quarter. ProShare Advisors LLC now owns 207,271 shares of the medical device supplier valued at $10,412,000 after purchasing an additional 43,213 shares during the period. 85.82% of the shares are held by institutional investors and hedge funds.

About LeMaitre Vascular (Get a rating)

LeMaitre Vascular, Inc designs, markets, sells, services and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. It offers an angioscope, a fiber optic catheter used to view the lumen of a blood vessel; embolectomy catheters for removing blood clots from arteries or veins; occlusion catheters that temporarily block blood flow; infusion catheters for infusing blood and other fluids into the vascular system; and thrombectomy catheters, which feature a silicone balloon to remove thrombus in the venous system.

Recommended Stories

Get a Free Copy of Zacks’ LeMaitre Vascular (LMAT) Research Report

For more information on Zacks Investment Research’s research offerings, visit Zacks.com

Earnings History and Estimates for LeMaitre Vascular (NASDAQ:LMAT)

Get news and reviews for LeMaitre Vascular Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for LeMaitre Vascular and related companies with MarketBeat.com’s FREE daily email newsletter.

Sallie R. Loera